Sorin rejects analysts' forecast of divestment
This article was originally published in Clinica
Sorin has dismissed speculation that it may divest its renal care business. Analysts at Morgan Stanley Dean Witter distributed a report on the Italian biomedical company last month which said: "Although [the renal care business] is profitable and generates cash, we believe, based on the company's stated strategy, that Sorin would entertain exiting the business if the right opportunity, for example an attractive cardiovascular surgery business, came along."
You may also be interested in...
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.